The role of LSD1 in AML has been evaluated and it was found that both pharmacological and genetic ablation of LSD1 is one of the few interventions ever shown to reduce leukemic stem cell (LSC) potential and AML cell engraftment in mice (21, 22). This evidence concerns the gene KDM1A and acute myeloid leukemia.